MX2010001242A - Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos. - Google Patents

Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.

Info

Publication number
MX2010001242A
MX2010001242A MX2010001242A MX2010001242A MX2010001242A MX 2010001242 A MX2010001242 A MX 2010001242A MX 2010001242 A MX2010001242 A MX 2010001242A MX 2010001242 A MX2010001242 A MX 2010001242A MX 2010001242 A MX2010001242 A MX 2010001242A
Authority
MX
Mexico
Prior art keywords
cannabidiol
prodrugs
methods
compositions
same
Prior art date
Application number
MX2010001242A
Other languages
English (en)
Inventor
Miroslaw Jerzy Golinski
Audra Lynn Stinchcomb
Jeffrey Lynn Howard
Dana Carmel Hammell
Stam Lee Banks
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of MX2010001242A publication Critical patent/MX2010001242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C07C69/68—Lactic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

En la presente, se describen profármacos de canabidiol, métodos para elaborar profármacos de canabidiol, formulaciones que comprenden profármacos de canabidiol y métodos para utilizar canabidioles. Una modalidad descrita en la presente se relaciona con la administración transdérmica o tópica de un profármaco de canabidiol para tratar y prevenir enfermedades y/o trastornos.
MX2010001242A 2007-07-30 2008-07-30 Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos. MX2010001242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95274607P 2007-07-30 2007-07-30
PCT/US2008/071659 WO2009018389A1 (en) 2007-07-30 2008-07-30 Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same

Publications (1)

Publication Number Publication Date
MX2010001242A true MX2010001242A (es) 2010-07-02

Family

ID=40011326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001242A MX2010001242A (es) 2007-07-30 2008-07-30 Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.

Country Status (10)

Country Link
US (1) US8293786B2 (es)
EP (1) EP2176208B1 (es)
JP (1) JP2010535238A (es)
CN (1) CN101815697A (es)
CA (1) CA2694325C (es)
DK (1) DK2176208T3 (es)
ES (1) ES2534900T3 (es)
MX (1) MX2010001242A (es)
PT (1) PT2176208E (es)
WO (1) WO2009018389A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
CA2694325C (en) 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US8829043B2 (en) 2008-02-08 2014-09-09 Nektar Therapeutics Oligome-cannabinoid conjugates
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
MX2011011514A (es) * 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
US20110052694A1 (en) * 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
EP2507269B1 (en) * 2009-12-02 2014-10-29 W.R. Grace & Co.-Conn. Three and four atom bridged dicarbonate compounds as internal donors in catalysts for polypropylene manufacture
US8481560B2 (en) 2010-04-02 2013-07-09 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20110245288A1 (en) 2010-04-02 2011-10-06 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
MX2015008766A (es) * 2013-01-08 2016-03-07 Yissum Res Dev Co Compuestos cbd fluorados, composiciones y usos de los mismos.
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
US9597279B2 (en) 2014-02-28 2017-03-21 HDDC Holdings, LLC Anti-aging dermal composition comprising herbal extracts
EP3134393B1 (en) 2014-04-21 2020-12-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cyclohexenyl compounds, compositions comprising them and uses thereof
US20150324942A1 (en) * 2014-05-09 2015-11-12 Aari Ruben Selective enhancement of cannabis
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN104277917B (zh) * 2014-10-24 2018-02-09 汉康(云南)生物科技有限公司 一种富含***二酚的工业***精油提取方法及其提取设备
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2999764A1 (en) 2015-09-22 2017-03-30 Vitality Biopharma, Inc. Cannabinoid glycoside prodrugs and methods of synthesis
US10933008B1 (en) 2015-10-25 2021-03-02 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof
US10709681B2 (en) 2016-01-29 2020-07-14 University Of Mississippi Biologically active cannabidiol analogs
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
WO2017181118A1 (en) * 2016-04-15 2017-10-19 Full Spectrum Laboratories Ltd Biosynthesis of cannabinoid prodrugs
EP3463304A4 (en) * 2016-05-24 2020-01-08 Bol Pharma Ltd. COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US20170362195A1 (en) * 2016-06-16 2017-12-21 Full Spectrum Laboratories Ltd Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CN107137604A (zh) * 2017-03-22 2017-09-08 哈尔滨惠美佳生物科技有限公司 一种具有抗焦虑作用的***二酚液体制剂及其制备方法
US11207291B2 (en) 2017-05-09 2021-12-28 Graphium Biosciences, Inc. Antimicrobial compositions comprising cannabinoids and methods of using the same
CN111183127B (zh) 2017-08-07 2023-02-21 南迪亚公司 ***二酚的共晶
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有***二酚和/或次***二酚的组合物及其在治疗痛经中的应用
US20200207782A1 (en) * 2017-09-22 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd Chemically activated water-soluble prodrug
WO2019064234A1 (en) 2017-09-28 2019-04-04 Zynerba Pharmaceuticals, Inc. TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CA3090545A1 (en) 2018-02-28 2019-09-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20190328884A1 (en) * 2018-04-30 2019-10-31 Chemic Laboratories, Inc. Compositions and methods of their use
GB201807942D0 (en) 2018-05-16 2018-06-27 Klaria Pharma Holding Ab Pharmaceutical formulation
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 ***二酚组合物及其用途
WO2020041326A1 (en) 2018-08-20 2020-02-27 Berkowitz Barry A Applications of known and novel cannabinoids
US11376227B2 (en) 2018-09-04 2022-07-05 Babak Ghalili Cannabinoid and menthol gum and lozenge compositions and methods
US11235013B2 (en) 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10987321B2 (en) * 2018-09-04 2021-04-27 Babak Ghalili Cannabinoid and anesthetic compositions and methods
US20200069604A1 (en) * 2018-09-04 2020-03-05 Babak Ghalili Cannabinoid and anesthetic compositions and methods
US10813889B2 (en) 2018-09-04 2020-10-27 Babak Ghalili Cannabinoid and menthol compositions and methods
US11147775B2 (en) 2018-09-04 2021-10-19 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
WO2020089424A1 (en) 2018-10-31 2020-05-07 Enantia, S.L. Solid compositions of cocrystals of cannabinoids
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 ***二酚类化合物的制备方法
JP2022539523A (ja) * 2019-06-24 2022-09-12 ダイヴァース バイオテック， インコーポレイテッド カンナビノイド抱合分子
EP4034100A4 (en) * 2019-09-26 2023-10-11 Firstlight Pharmaceuticals LLC CANNABINOID PRODRUG COMPOUNDS
EP3836894A1 (en) * 2019-10-25 2021-06-23 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences Llc PRODRUGS OF FULVESTRANT
EP3861996A1 (en) * 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
CA3074150A1 (en) * 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021177936A1 (en) * 2020-03-02 2021-09-10 Babak Ghalili Cannabinoid and anesthetic compositions and methods
WO2021177937A1 (en) * 2020-03-02 2021-09-10 Babak Ghalili Cannabinoid and menthol compositions and methods
CN111423312B (zh) * 2020-03-31 2021-05-07 云南西草资源开发有限公司 一种利用紫色硫细菌发酵提取***二酚的方法及其应用
EP4135687A4 (en) * 2020-04-17 2024-04-17 Univ Connecticut POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CN111557900B (zh) * 2020-05-22 2023-05-12 广州大洲生物医药科技有限公司 ***二酚乳膏剂，其制备方法及用途
US20230226200A1 (en) * 2020-06-05 2023-07-20 London Pharmaceuticals And Research Corporation Cannabinoid-hyaluronic acid bioconjugates
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CN112279786B (zh) * 2020-11-23 2023-05-09 汤文建 一种***二酚氨基甲酸酯类化合物、药物制剂及制备方法与应用
CN116234812A (zh) * 2020-11-25 2023-06-06 成都百裕制药股份有限公司 ***素类化合物的制备方法
KR20230140566A (ko) * 2021-02-04 2023-10-06 아리엘 싸이언티픽 이노베이션스 엘티디. 히알루론산 cbd 접합체의 제조
CN116253642A (zh) * 2021-04-06 2023-06-13 山东绿叶制药有限公司 ***二酚前药及其药物组合物和应用
TW202304857A (zh) * 2021-04-07 2023-02-01 加拿大商美蒂普爾製藥公司 內生性***素系統靶向前驅藥及其治療用途
WO2023009817A2 (en) * 2021-07-29 2023-02-02 Emory University Phosphate prodrugs of cannabinoids
CN113735709B (zh) * 2021-09-17 2022-03-18 中国农业科学院农产品加工研究所 一种***二酚-2-丁酸酯及其应用
CN113666824B (zh) * 2021-09-17 2022-03-22 中国农业科学院农产品加工研究所 一种***二酚-2-丙酸酯及其应用
CN116253671A (zh) * 2021-12-10 2023-06-13 德义制药有限公司 一种***二酚衍生物及其制备方法和应用
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
CN114315680B (zh) * 2022-03-07 2022-07-19 中国农业科学院农产品加工研究所 一种***二酚-2-吡咯烷酸酯及其应用
CN114292249B (zh) * 2022-03-07 2022-07-19 中国农业科学院农产品加工研究所 一种***二酚-2-哌嗪酸酯及其应用
WO2023235386A1 (en) * 2022-05-31 2023-12-07 Trait Biosciences, Inc. Water-soluble cannabinoid prodrugs compositions and methods of synthesizing the same
WO2024009324A1 (en) * 2022-07-08 2024-01-11 Council Of Scientific & Industrial Research Prodrugs of cannbidiol [cbd]-type phytocannabinoids and a process for preparation thereof
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968125A (en) 1973-11-05 1976-07-06 Eli Lilly And Company Dihydroxyhexahydrodibenzo[b,d]pyrans
US4260764A (en) 1976-12-22 1981-04-07 Pfizer Inc. 9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor
US4235913A (en) 1977-06-07 1980-11-25 Pfizer Inc. 9-Hydroxyhexahydrodibeno[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo]b,d]pyrans
US4133819A (en) 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4263438A (en) 1977-09-13 1981-04-21 Pfizer Inc. 3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics
US4283569A (en) 1977-09-13 1981-08-11 Pfizer Inc. Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives
US4270005A (en) 1977-11-14 1981-05-26 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
US4243674A (en) 1978-06-12 1981-01-06 Pfizer Inc. 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore
US4206225A (en) 1978-09-22 1980-06-03 Pfizer Inc. 2,10-Disubstituted dibenzo[b,d]pyrans and benzo[c]quinolines
US4371720A (en) 1980-09-19 1983-02-01 Pfizer Inc. 2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives
US4663474A (en) 1983-02-22 1987-05-05 Pfizer Inc. Synthetic intermediates for a chiral 3-(substituted-phenyl)-4-(3-hydroxypropyl) cyclohexanol
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5223262A (en) 1989-02-23 1993-06-29 University Of Utah Transdermal delivery system utilizing one way membranes
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5166145A (en) 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
IL101927A0 (en) 1992-05-19 1992-12-30 Yissum Res Dev Co Probe for cannabinoid receptors
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5389375A (en) * 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
IT1271267B (it) 1994-12-14 1997-05-27 Valle Francesco Della Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
KR19990082330A (ko) 1996-02-06 1999-11-25 미즈노 마사루 신규 화합물 및 이의 의약 용도
EP0971588B1 (en) 1997-01-21 2004-03-17 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
US6132762A (en) 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US5804592A (en) 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
JPH1180124A (ja) 1997-07-11 1999-03-26 Japan Tobacco Inc キノリン化合物及びその医薬用途
US6162829A (en) 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
WO1999024471A1 (en) 1997-11-10 1999-05-20 The Research Foundation Of State University Of New York Opiate, cannabinoid, and estrogen receptors
DE69936640D1 (de) 1998-04-21 2007-09-06 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
US5847128A (en) 1998-05-29 1998-12-08 Virginia Commonwealth University Water soluble derivatives of cannabinoids
IT1302264B1 (it) 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
AU1833600A (en) 1998-11-24 2000-06-19 Andreas Goutopoulos Cannabimimetic lipid amides as useful medications
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
WO2000045813A1 (en) * 1999-02-04 2000-08-10 New Millennium Pharmaceutical Research, Inc. Method for enhancement of delivery of thc by the administration of its prodrugs via the nasal route
JP2002539246A (ja) * 1999-03-22 2002-11-19 イミュジェン ファーマシューティカルズ インコーポレイティッド 免疫疾患の治療
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US6503532B1 (en) 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
US7084150B2 (en) 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE602004024963D1 (de) * 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US20090068143A1 (en) * 2004-10-22 2009-03-12 Pharmos Corporation Orally effective cannabinoid analogs
JP2008542359A (ja) * 2005-05-31 2008-11-27 ファーモス コーポレイション 治療的活性を有するベンゾフラン誘導体
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
CA2694325C (en) 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same

Also Published As

Publication number Publication date
CA2694325C (en) 2015-09-22
US8293786B2 (en) 2012-10-23
DK2176208T3 (en) 2015-04-27
WO2009018389A1 (en) 2009-02-05
EP2176208B1 (en) 2015-01-21
WO2009018389A4 (en) 2009-04-23
JP2010535238A (ja) 2010-11-18
CN101815697A (zh) 2010-08-25
ES2534900T3 (es) 2015-04-30
PT2176208E (pt) 2015-05-11
EP2176208A1 (en) 2010-04-21
US20090036523A1 (en) 2009-02-05
CA2694325A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2010001242A (es) Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MX363435B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
MX2018015635A (es) Composiciones y metodos para la modulacion de division de smn2 en un sujeto.
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
EP2513343A4 (en) METHODS AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
HK1117824A1 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2012142520A3 (en) Unit dose form for oral administration
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
WO2008070268A3 (en) Pharmaceutical compositions
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
UY30986A1 (es) Derivados fluorinados de deferiprona
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal